AVEO’s Fotivda Combo Flunks Phase III Renal Cell Carcinoma Study
AVEO Oncology on Thursday announced that its oral drug Fotivda (tivozanib) fell short of its primary efficacy endpoint in the Phase III TiNivo-2 study in renal cell carcinoma. The Boston, MA–based biotech did not provide detailed data in its news release, …